Condition: Esophagus Cancer · Sponsor: The First Affiliated Hospital of Henan University of Science and Technology
The aim of this study is to compare outcomes in Chinese patients with locally advanced resectable esophageal squamous cell cancer who have received either surgery or definitive chemoradiation (CRT) by the randomized, open-label, multicenter trial.
This description comes directly from the study's public registry record.
Shegan Gao, MD, PhD · +86 18638859977 · gsg112258@163.com
Ruinuo Jia, MD · +86 18537950766 · jiaruinuo@163.com
Always discuss trial participation with your own doctor first.
| Anyang Tumor Hospital | Anyang, Henan, China | Recruiting |
| The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology | Luoyang, Henan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02972372